Fondazione IRCCS Policlinico San Matteo
N° Verde Prenotazioni (rete fissa) 800.638638 | 02 99.95.99 (da cellulare)
       
Gruppi di Ricerca

Terapie innovative in Oncologia - Gruppo di Ricerca

REFERENTE - GROUP LEADER
Prof. PEDRAZZOLI Paolo
CURRICULUM VITAE REFERENTE

CV Prof. Pedrazzoli Paolo

 
GROUP MEMBERS

Agustoni F., Chiellino S., Corallo S., Galli G., Ferrari A. & OCTO Team, Ferraris E., Gandini C., Lasagna A., Monaco T.  & nurses group, Pagani A., Rizzo G., Secondino S.

 
  •  

    RESEARCH PROJECTS

    • Clinical and translational studies in solid tumors (selection)
      • Phase I, II and III studies with new drugs and procedures in Lung Cancer stage III and IV, Breast Cancer, Mesothelioma and other solid tumors
      • Germ cell tumors: Role of miRNA in solid tumor (miRNA371 in germ cell cancer); autologous stem cell transplantation (prospective and retrospective studies)
      • Cell therapy in Nasopharyngeal Carcinoma and Colorectal cancer, stem cell transplantation
      • Immunotherapy including prediction of response 
      • Alliance against Cancer (ACC): Gersom; and Lung Working groups / Radiomiomics studies in collaboration with Radiotherapy  and Radiology Units
      • Preclinical studies in small bowel adenocarcinoma, colorectal Cancer, Breast Cancer
    • Nutritional support in cancer patients, including drafting of national and international recommendations
      • Immunonutrition in head&neck cancer and lung cancer; artificial nutrition in gastric cancer 
      • Assessment of nutritional risk and body composition in various oncological settings
      • Effects of amino-acid supplementation on lymphocytes, in patients with advanced gastrointestinal cancers 
      • ACC Working Groups: Survivorship care and Nutrition Support in cancer patients
    • Viral diseases and cancer, including drafting of national guidelines
      • Immunogenicity of anti-SARS-CoV-2 and HZ vaccines in cancer patients 
      • Evaluation of T-cell response in patients with occult hepatitis B infection during immunotherapy
      • Evaluation of gut microbiota in breast cancer and in patients undergoing immunotherapy
      • Implications for Immunotherapy: Single-Cell profiling of liver-infiltrating immune cells of patients with NASH- and virus-related HCC.
  •  

    5 BEST PAPERS

  •  

    RUNNING FUNDS

  •  

    NATIONAL AND INTERNATIONAL STRATEGIC COLLABORATIONS